#cancer therapies #Intensity Therapeutics #INT230-6

Intensity Therapeutics at the H.C. Wainwright Conference

In a significant move for the biotechnology sector, Intensity Therapeutics, Inc. (NASDAQ: INTS) will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026. This prominent gathering, held at the luxurious Lotte New York Palace Hotel, is expected to showcase the latest advancements in biotechnology and investment opportunities.

Key Presentation Details

Intensity Therapeutics is set to unveil its groundbreaking approaches to cancer treatment, highlighting its proprietary drug INT230-6. This innovative therapy employs a unique non-covalent conjugation technology designed to enhance the effectiveness of established anti-cancer agents. The company's president and CEO, Mr. Lewis H. Bender, will present insights into the company’s pioneering endeavors in oncology on September 11, 2026, at 7:00 AM ET. The presentation will be available on-demand via a live webcast, ensuring broader access to interested parties. A replay of the presentation will also be archived and accessible for about 90 days.

About INT230-6

INT230-6 represents Intensity Therapeutics' lead investigational product candidate, meticulously engineered for direct intratumoral injection. This treatment comprises two potent anti-cancer agents, cisplatin and vinblastine sulfate, combined with an innovative diffusion-enhancing molecule. This formulation is designed to penetrate tumors effectively, delivering significant cytotoxic impact while maintaining a favorable safety profile. Notably, INT230-6 has demonstrated dual capabilities by not only controlling local disease but also igniting an immune response against the tumors, potentially transforming how various malignancies are treated.

In clinical trials, INT230-6 has shown promising results, notably in the Phase 1/2 study involving metastatic cancers and the ongoing Phase 2 randomized controlled trial in locally advanced breast cancer (the